Moduladores enzimáticos
Moduladores de enzimas são compostos que podem aumentar ou inibir a atividade de enzimas, regulando assim a taxa de reações bioquímicas. Esses moduladores desempenham um papel crucial no controle de vias metabólicas, sinalização celular e vários processos fisiológicos. Os moduladores de enzimas são amplamente utilizados em pesquisa e desenvolvimento de medicamentos para estudar as funções enzimáticas e desenvolver agentes terapêuticos. Na CymitQuimica, oferecemos uma ampla gama de moduladores de enzimas de alta qualidade para apoiar sua pesquisa em regulação enzimática e descoberta de medicamentos.
Subcategorias de "Moduladores enzimáticos"
Foram encontrados 693 produtos de "Moduladores enzimáticos"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
GSK3 (3-13)/crosstide-[S]
A glycogen synthase kinase 3β- (GSK3β-) / crosstide fragment representing the phosphorylation site on GSK3β-. GSK3β- is a serine/threonine kinase which regulates glycogen synthase activity and is a key mediator of vertebrate development, tumourigenesis and cell differentiation. GSK3β- is phosphorylated by activated AKT/protein kinase B on serine 9- promoting its inactivation.Pureza:Min. 95%Cor e Forma:PowderPeso molecular:1,193.6 g/molSRT2104
CAS:Activator of SIRT1 deacetylaseFórmula:C26H24N6O2S2Pureza:Min. 95%Cor e Forma:PowderPeso molecular:516.64 g/molPHA 793887
CAS:Inhibitor of cyclin dependend kinases
Fórmula:C19H31N5O2Pureza:Min. 95%Cor e Forma:SolidPeso molecular:361.24778Fluvastatin lactone
CAS:HMG-CoA reductase inhibitorFórmula:C24H24FNO3Pureza:Min. 95%Cor e Forma:PowderPeso molecular:393.45 g/molNrf2 (69-84)
Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) and its negative regulator Kelch-Like ECH-Associated Protein 1 (Keap1) provide vital protection in maintaining cellular redox. In parallel, Nrf2 also aids the resolution of inflammation and also tissue repair. In homeostatic conditions, the transcription factor Nrf2 is controlled in a cytoplasmic complex with Keap1 with ubiquitination and protein degradation. Nrf2 has been linked to numerous cancers due to mutations affecting the binding region of Nrf2 to Keap1, resulting in Nrf2 dissociating from the complex. Nrf2 constitutively accumulates in the nucleus and activation of prosurvival genes that promote cancer cell proliferation.The Neh2 region of Nrf2 interacts with Keap1, as shown by nuclear magnetic resonance spectroscopy. The 16 amino acid peptide (AFFAQLQLDEETGEFL) (69-84) flanks the conserved ETGE motif and can replicate the binding to keap1.Therapeutics targeting the Nrf2 signalling pathway and activation of Nrf2 is a keen area of research, with many cancers being linked to Nrf2, particularly pancreatic cancer. Additionally, activation of Nrf2 has become a possible target as a treatment for COVID. Nrf2 (69-84) replicating full-length Nrf2 binding has been helpful in all cases.Pureza:Min. 95%Cor e Forma:PowderPeso molecular:1,856.9 g/mol[G]-JAK1 peptide (1015-1027) p(Y1022)
This peptide is phosphorylated by Janus kinase 1 (JAK1) and is an ideal substrate for use in kinase assays. The JAK family of kinases is essential for the signalling of a host of immune modulators in tumour, stromal, and immune cells where they are highly expressed. JAK family proteins mediate the signalling of the interferon (IFN), IL-6, and IL-2 families of cytokines.JAK kinases are associated with cytokine receptors. Cytokine binding to these receptors results in activation of JAK kinases and receptor phosphorylation. Phosphorylated cytokine receptors recruit STAT proteins, which are then phosphorylated by the activated JAK kinases. Phosphorylated STAT proteins form homo- and hetero-dimers that translocate into the nucleus and function as transcription factors.This JAK1 substrate peptide contains an N-terminal Glycine-residue and a phospho-tyrosine-residue.Pureza:Min. 95%Cor e Forma:PowderPeso molecular:1,710.7 g/molAZD 2098
CAS:A potent and selective agonist of CCR4 chemokine receptor with IC50 values ranging from 10 to 25 nM across different species. CCR4 is involved in activation and migration of Th2 lymphocytes to the lungs in response to allergens. Treating sensitised rats results in reduced inflammation of lung tissue.Fórmula:C11H9Cl2N3O3SPureza:Min. 95%Cor e Forma:PowderPeso molecular:334.18 g/molSorafenib tosylate - Bio-X ™
CAS:Sorafenib is a drug that belongs to the class of multikinase inhibitors. It inhibits a number of kinases, including the Mcl-1 protein, which is involved in apoptosis along with blocking picolinic acid (PA), an endogenous metabolite involved in apoptosis signal transduction. Sorafenib also binds to epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting the production of proteins that are required for angiogenesis, thus blocking the formation of new blood vessels. Sorafenib may also inhibit P-glycoprotein (Pgp) activity. Overall, these cytotoxic effects give Sorafenib anti-tumor properties, inhibiting angiogenesis and cellular transformation, which are the two main processes of tumor growth and metastasis. Sorafenib tosylate has been shown to be effective against a range of solid tumors such as breast, prostate and lung cancers and is also used for the treatment of metastatic colorectal cancer and renal cell carcinoma. A combination therapy group found that sorafenib was more effective when used with interferon alfa-2b for the treatment of advanced renal cell carcinoma. Sorafenib tosylate also has the potential for drug interactions with other drugs that are metabolized by cytochrome P450 enzymes.
Sorafenib tosylate is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.Fórmula:C21H16ClF3N4O3•C7H8O3SPureza:Min. 95%Cor e Forma:PowderPeso molecular:637.03 g/molTTK 21
CAS:CBP/p300 histone acetyltransferase activatorFórmula:C17H15ClF3NO2Pureza:Min. 95%Cor e Forma:PowderPeso molecular:357.76 g/molErlotinib mesylate
CAS:EGFR tyrosine kinase inhibitorFórmula:C23H27N3O7SPureza:Min. 95%Cor e Forma:White PowderPeso molecular:489.54 g/molLGK 974
CAS:Inhibits Wnt signaling pathway by targeting porcupine, a membrane-bound O-acyltransferase involved in the palmitoylation and secretion of Wnt. Anti-cancer properties of LGK 974 have been demonstrated in various tumor models of breast cancer, head and neck squamous cell carcinoma and glioblastoma. Blocks LPS-mediated inflammatory response in epithelial and endothelial cells.
Fórmula:C23H20N6OPureza:Min. 98 Area-%Cor e Forma:White PowderPeso molecular:396.40 g/molNitric oxide synthase, endothelial (492-507)
Peptide derived from the endothelial nitric oxide synthase which synthesises nitric oxide in order to protect endothelial cells from vascular diseases, atherosclerosis and thrombosis.Pureza:Min. 95%Cor e Forma:PowderPeso molecular:1,788.1 g/molFluvastatin sodium salt - Bio-X ™
CAS:Fluvastatin is a statin that lowers blood cholesterol and triglycerides by inhibiting HMG-CoA reductase, an enzyme that plays a critical role in the synthesis of cholesterol. Fluvastatin has also been shown to reduce the incidence of myocardial infarction, and to reduce atherosclerotic lesions in animal models, reducing the incidence of cardiovascular disease. Fluvastatin also has been shown to inhibit the activation of toll-like receptor 4 (TLR4) by lipopolysaccharide (LPS), which may be related to its anti-inflammatory effects. Furthermore, through lowering blood cholesterol, Fluvastatin also inhibits tubulointerstitial injury and prevents renal damage caused by high concentrations of the lipid.Fórmula:C24H25FNNaO4Pureza:Min. 98%Peso molecular:433.45 g/molTAK 243
CAS:A potent inhibitor of ubiquitin activating enzyme E1. Lowers ubiquitin conjugates in cells, thereby disrupting cell signalling, cell cycle progression and repair of DNA damage. Anti-tumor effects have been demonstrated in vitro and in vivo. TAK 243 has been used to study the biology of ubiquitins and its potential as anti-cancer therapy.Fórmula:C19H20F3N5O5S2Pureza:Min. 95%Cor e Forma:White Off-White PowderPeso molecular:519.52 g/molN-[3-(1,3-Benzodioxol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-N',N'-dimethyl-propane-1,3-diamine
Selective inhibitor of the mutated RET variant RETV804M, which is the anticipated drug-resistant RET mutant that can occur in tumours treated with kinase inhibitors. The compound has a biochemical IC50 of 0.02 µM and selectivity for purified RETV804M over purified RET and KDR of 3.7 and 110, respectively. The efficacy of the compound was shown also in cell cultures with IC50 of 4.4 µM, and cell assay selectivity for RETV804M over RET and KDR of 0.89 and 2.3, respectively.Fórmula:C18H21N5O2Pureza:Min. 98 Area-%Cor e Forma:PowderPeso molecular:339.39 g/molI-RW
The peptide IRW, characterised from egg protein, exhibits inhibitory properties against the angiotensin converting enzyme (ACE2) and could be used to prevent cardiovascular disease with further research. Treatment of hypertensive mice with IRW induced endothelium-dependent vasorelaxation and reduced vascular inflammation. The IRW tripeptide acts as anti-hypertensive by upregulating ACE2 activity via the Mas receptor (MasR) and upregulating Akt/eNOS signalling in the aorta. IRW also induces superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) activity. These may play a factor in IRW's role as an anti-inflammatory. IRW shows promise as a nutraceutical for inflammatory conditions and a tool for drug development in cardiovascular disease.Pureza:Min. 95%Peso molecular:1,830.9 g/molMEK162
CAS:Inhibitor of MEK1/2 kinase enzymes; antineoplasticFórmula:C17H15BrF2N4O3Pureza:Min. 95%Cor e Forma:White/Off-White SolidPeso molecular:441.23 g/molIQVPL (EYGF-56)
During extraction of lecithin from egg yolk, peptide by-products can be isolated and purified by gel filtration. Within the by-products this has led to the discovery of biologically active value-added products. The egg yolk gel filtration (EFGF) fractions were analysed for their antioxidant and angiotensin converting enzyme (ACE) inhibitory activities. EYGF-56 predominantly contained 3 peptides - SDNRNQGY, IQVPL, and KGLWE. IQVPL in EYGF-56 was found to have minimal antioxidant activity. YPSPV showed some angiotensin converting enzyme (ACE) inhibitory activity.Pureza:Min. 95%Peso molecular:567.4 g/molDanusertib
CAS:Inhibitor of aurora kinases
Fórmula:C26H30N6O3Pureza:Min. 95%Cor e Forma:White PowderPeso molecular:474.57 g/molK252c
CAS:Inhibitor of protein kinase PKCFórmula:C20H13N3OPureza:Min. 95%Cor e Forma:PowderPeso molecular:311.34 g/mol
![GSK3 (3-13)/crosstide-[S]](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FCRB1000548.webp&w=3840&q=75)
![[G]-JAK1 peptide (1015-1027) p(Y1022)](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FCRB1000480.webp&w=3840&q=75)
![N-[3-(1,3-Benzodioxol-5-yl)pyrazolo[1,5-a]pyrimidin-5-yl]-N',N'-dimethyl-propane-1,3-diamine](/_next/image/?url=https%3A%2Fstatic.cymitquimica.com%2Fproducts%2F3D%2Fthumb-webp%2FEB176309.webp&w=3840&q=75)
